Chandler Robinson - 24 Sep 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MNPR
Reported as of: 24 Sep 2026
Net transaction value: -$2,556,851
SEC form: 4
Accepted by SEC: 28 Sep 2026, 20:47:40 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Chandler Robinson filed Form 4 for Monopar Therapeutics (MNPR) on 28 Sep 2026.

Key facts

This page summarizes Chandler Robinson's Form 4 filing for Monopar Therapeutics (MNPR).
8 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Sep 2026, 20:47.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$2,556,851.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727334 Primary reporting owner

Robinson Chandler

Relationship: Chief Executive Officer, Director
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 28 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +14,056
Change %: +14%
Price: $30.00^*
Shares after: 113,323
Date: 24 Sep 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +15,000
Change %: +13%
Price: $14.00^*
Shares after: 128,323
Date: 24 Sep 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Sale

Transaction value: $910,718
Shares: -10,450
Change %: -8.1%
Price: $87.15
Shares after: 117,873
Date: 24 Sep 2026
Ownership: Direct
Footnotes: F1, F5

MNPR transaction

Common Stock

Sale

Transaction value: $847,758
Shares: -9,638
Change %: -8.2%
Price: $87.96
Shares after: 108,235
Date: 24 Sep 2026
Ownership: Direct
Footnotes: F1, F6

MNPR transaction

Common Stock

Sale

Transaction value: $744,501
Shares: -8,368
Change %: -7.7%
Price: $88.97
Shares after: 99,867
Date: 24 Sep 2026
Ownership: Direct
Footnotes: F1, F7

MNPR transaction

Common Stock

Sale

Transaction value: $53,874
Shares: -600
Change %: -0.6%
Price: $89.79
Shares after: 99,267
Date: 24 Sep 2026
Ownership: Direct
Footnotes: F1, F8

MNPR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 62,815
Date: 24 Sep 2026
Ownership: See Footnote
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -14,056
Change %: -48%
Price: $0.000000^*
Shares after: 15,044
Date: 24 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,056
Exercise price: $30.00
Footnotes: F1, F2

MNPR transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -15,000
Change %: -36%
Price: $0.000000^*
Shares after: 27,204
Date: 24 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $14.00
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

Footnote F2

On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

Footnote F3

On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.

Footnote F4

Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

Footnote F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

Footnote F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.